CATH2 Peptides Inhibit Streptococcus suis Growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Streptococcus suis infections, particularly in pigs and humans, are inadequate due to the emergence of antibiotic-resistant strains, necessitating the development of novel therapeutic methods for effective prevention and treatment.
Innovation Solution
The use of CATH2 derivatives, such as DCATH2 and its truncated forms, which exhibit potent antibacterial activity and immunomodulatory effects, are administered to inhibit the growth of Streptococcus suis and induce innate immune memory, thereby preventing and treating infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used for treating S. suis infections, then treatment effectiveness is initially good, but antibiotic resistance develops leading to treatment failure
Solution Approach 1:
The patent changes the chemical parameter of the treatment agent from conventional antibiotics to cathelicidin-derived peptides (CATH2 and derivatives). This parameter change enables the treatment to maintain effectiveness against S. suis while avoiding the development of antibiotic resistance, as the peptides work through a different mechanism of action that bacteria have not developed resistance against yet.
Solution Approach 2:
The patent utilizes cathelicidin-derived peptides which are composite in nature - they combine antimicrobial activity with immunomodulatory properties. The peptides not only directly inhibit bacterial growth but also enhance the host immune response, creating a multi-faceted treatment approach that addresses both the pathogen and the host's defense capability.
2Ease of operation
If conventional treatments are used, then current protocols are simple, but they fail to address emerging resistant strains
Solution Approach 1:
The cathelicidin-derived peptides exhibit broad-spectrum activity against multiple strains of S. suis, including resistant strains. The treatment agent serves multiple functions: direct bactericidal activity, inhibition of bacterial growth, and modulation of the host immune response. This multi-functionality makes the treatment universally effective across different strain types without requiring complex diagnostic procedures to select specific antibiotics.
3Reliability
If CATH2 derivatives are administered, then direct antibacterial activity is achieved, but the complexity of peptide administration increases
Solution Approach 1:
The patent uses synthetic copies of the natural cathelicidin peptide CATH2. These synthetic peptides can be produced through chemical synthesis or recombinant expression systems, allowing for standardized production and administration. The copying approach enables the complex peptide structure to be replicated consistently, making administration feasible through conventional peptide delivery methods without requiring complex device systems.
Data Source
AI summary
The invention relates to methods for inhibiting S. suis comprising administering to CATH2 or a derivative thereof and to methods for the treatment or prevention of a S. suis infection in a subject in need thereof, comprising administering CATH2 or a derivative thereof to the subject.